1-Methanesulfonyl-2-methyl-piperidine | 93423-86-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Methanesulfonyl-2-methyl-piperidine
• 英文别名: 2-Methyl-1-methylsulfonylpiperidine
• CAS: 93423-86-0
• 化学式: C₇H₁₅NO₂S
• mdl: MFCD01212004
• 分子量: 177.268
• InChiKey: DCQSAGOTUMTJGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-Methanesulfonyl-2-methyl-piperidine 在 ruthenium(IV) oxide 、 sodium chloride 作用下， 以 水 、 丙酮 为溶剂， 以50%的产率得到1-Methanesulfonyl-6-methyl-piperidin-2-one
  参考文献：
  名称：

  INDIRECT ELECTROOXIDATION OFN-PROTECTED AMINES TO AMIDES WITH A DOUBLE MEDIATORY SYSTEM CONSISTING OF RuO₄, AND Cl⁺

  摘要：

  在饱和NaCl-丙酮体系中，利用RuO4对N-保护脂肪胺进行间接电氧化转化，可以高产率地得到相应的酰胺。

  DOI：

  10.1246/cl.1984.1063

文献信息

• [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET MÉTHODES UTILISÉS POUR LA MODULATION DES KINASES ET INDICATIONS À CET EFFET
  申请人：PLEXXIKON INC

  公开号：WO2011063159A1

  公开（公告）日：2011-05-26

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述化合物或其盐、配方、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述化合物在抑制Ras突变细胞系增殖方面具有活性。还描述了使用这些方法来治疗疾病和病况，包括与B-Raf V600E突变蛋白激酶活性相关的疾病和病况，包括黑色素瘤、胶质瘤、胶质母细胞瘤、乳头状星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道癌和胆管癌。还描述了使用这些方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病况，包括急性疼痛、慢性疼痛或多囊肾病。
• WDR5 INHIBITORS AND MODULATORS
  申请人：Vanderbilt University

  公开号：US20180086767A1

  公开（公告）日：2018-03-29

  Described are compounds that disrupt the WDR5-MLL1 protein-protein interaction, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

  描述了破坏WDR5-MLL1蛋白-蛋白相互作用的化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗受试者疾病和症状的方法。
• [EN] REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS<br/>[FR] AGONISTES REV-ERB POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES À MÉDIATION PAR TH17
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021263278A1

  公开（公告）日：2021-12-30

  The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

  本公开提供了Formula IA和Formula IB的化合物及其作为REV-ERB-α选择性激动剂的药物组合物：其中R1、R2、R3、R4、R5、RX1、RX2、nA、nB、X、Y和Z如本文所述。这些化合物在各种方法和用途中非常有用，例如用于治疗包括高血糖、血脂异常、动脉粥样硬化、自身免疫和炎症性疾病等疾病，以及作为癌症治疗药物，如用于治疗胶质母细胞瘤、肝细胞癌和结直肠癌，以及用于免疫肿瘤学目的。
• Thienopyrrole compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20060167246A1

  公开（公告）日：2006-07-27

  The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由下式[I]所表示的噻吡咯烷化合物，其中每个符号如规范中定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和含有该化合物作为活性成分的治疗剂。本发明的化合物基于HCV聚合酶抑制活性显示抗HCV活性，并且可用作丙型肝炎的预防或治疗剂。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。